Tissue composition quantitatively reproduces bulk transcriptomic differences between paired primary gastric tumours and solid peritoneal metastases
This study demonstrates that quantitative differences in tissue composition, specifically a reduction in epithelial content, fully account for the bulk transcriptomic contrasts observed between primary gastric tumors and their peritoneal metastases, indicating that claims of cancer cell state changes from such bulk comparisons require cell-resolved validation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Gastric cancer, a disease that begins in the lining of the stomach, is a leading cause of death worldwide. One of its most dangerous behaviors is spreading to the peritoneum, the thin membrane that lines the abdominal cavity and wraps around the organs. When cancer reaches this space, it often forms hard, solid patches on the tissue. Understanding how these metastatic patches differ from the original stomach tumor is critical for finding better treatments. Scientists have long studied these differences by taking samples of both the original tumor and the spread, then measuring the activity of thousands of genes in a single batch of tissue. This method, known as bulk transcriptomics, gives a broad picture of what is happening in the sample. However, a sample is rarely just cancer cells. It is a mixture of the malignant cells, the body's own immune defenders, structural fibers, fat cells, and blood vessels. When researchers see a change in gene activity between a stomach tumor and a peritoneal patch, it has been unclear whether the cancer cells themselves have changed their behavior, or if the change is simply because the mixture of surrounding tissues is different.
A team of researchers set out to solve this puzzle using a rigorous, pre-planned approach to analyze data from patients who had both a primary stomach tumor and a solid peritoneal metastasis. They focused on a specific set of one hundred genes that are known to be active in cancer cells but quiet in normal tissue. Before looking at the patient data, they locked in their methods, deciding exactly which genes to count and how to score them, ensuring their results would not be influenced by what they hoped to find. When they compared the paired samples from seventeen patients, they found a consistent pattern: the activity of these cancer-cell genes was significantly lower in the peritoneal metastases than in the original stomach tumors. In fifteen of the seventeen patients, the score dropped. At first glance, this might suggest that the cancer cells in the abdomen have become less active or have changed their internal state.
However, the researchers did not stop at this initial observation. They looked closely at the other tissues present in the samples. They found that the peritoneal metastases contained much higher amounts of fibroblasts, which are structural cells that build connective tissue, as well as more fat cells and blood vessel cells. Conversely, the samples from the peritoneum contained far fewer markers for the specific type of stomach lining cells found in the original tumor. This suggested that the drop in the cancer-gene score was not because the cancer cells had changed, but because the cancer cells were simply a smaller part of the total mixture in the peritoneal sample. To test this, the team used a mathematical model to see how much the composition of the tissue would need to change to explain the drop in gene activity. They calculated that a difference of roughly thirty percentage points in the amount of epithelial tissue—meaning the cancer cells and normal stomach lining cells—was enough to reproduce the entire observed difference. In other words, if the cancer cells had stayed exactly the same, but the sample simply contained thirty percent less of them and thirty percent more of the surrounding support tissue, the gene scores would look exactly as they did in the study.
The team confirmed this explanation through several different checks. They tested their findings using different ways of calculating the scores and found the same result. They also looked at a separate group of patients and found that the gene scores they were measuring tracked directly with the amount of tumor tissue visible under a microscope; when the tumor tissue was more abundant, the scores were higher. Furthermore, they examined data from single-cell studies, which can look at individual cells rather than a mixed batch. Although the number of cancer cells found in the peritoneal samples was too small to draw a definitive conclusion on its own, the few cells that were found showed high activity levels, similar to the cancer cells in the original tumors. This supported the idea that the cells themselves had not changed, but were simply harder to detect in the mixed tissue.
The study concludes that the apparent differences in gene activity between primary stomach tumors and their peritoneal metastases are largely driven by the changing composition of the tissue sample, not by a fundamental change in the cancer cells' internal programs. The researchers argue that when scientists compare bulk tissue samples from different sites, they must account for the fact that the "soup" of cells is different. A drop in a cancer-gene score does not necessarily mean the cancer has become less aggressive or changed its nature; it may simply mean the sample contains more of the body's supporting tissues and fewer cancer cells. This finding does not erase the biological reality that the peritoneal environment is unique and rich in specific cell types like fat and fibroblasts, which are known to influence cancer. However, it clarifies that the tools used to measure cancer cell behavior in mixed samples can be misleading if the changing mixture of the tissue is not explicitly considered. For future research to truly understand how cancer cells adapt as they spread, scientists will need either to isolate the cancer cells individually or to use models that explicitly separate the signal of the cancer cells from the noise of the surrounding tissue.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.